EyePoint (EYPT) Receivables - Other (2020 - 2021)
EyePoint (EYPT) posted Receivables - Other of $414000.0 for Q4 2021, up 298.08% sequentially from $104000.0 in Q4 2020, and up 298.08% YoY from $104000.0 in Q4 2020.
Powered by 
Analysis
EyePoint (EYPT) Receivables - Other (2020 - 2021) Analysis & Trends
EyePoint has reported Receivables - Other for 2 years, with the latest figure at $414000.0 in Q4 2021.
- Quarterly Receivables - Other rose 298.08% year-over-year to $414000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $414000.0 (up 298.08% YoY) and the FY2021 annual result came in at $414000.0, up 298.08% from the prior year.
- Receivables - Other rose to $414000.0 in Q4 2021 per EYPT's latest filing, from $104000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $414000.0 in Q4 2021 and troughed at $104000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |